227Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study-Reference-Cited by-同舟云学术

227Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study

Published:2021-10-01 Issue:8 Volume:36 Page:672-681
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Lindén Ola¹,Bates Andrew T.²,Cunningham David³,Hindorf Cecilia⁴,Larsson Erik⁴,Cleton Adriaan⁵,Pinkert Joerg⁶,Huang Funan⁷,Bladt Friedhelm⁸,Hennekes Hartwig⁸,Oedegaardstuen Liv-Ingrid⁹,Sturm Isrid⁸,McNamara Christopher¹⁰

Affiliation:

1. Department of Oncology, Lund University Hospital, Lund, Sweden.

2. Clinical Oncology Department, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.

3. Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital, London, United Kingdom.

4. Department of Radiation Physics, Skåne University Hospital, Lund, Sweden.

5. Translational Sciences Asia, Bayer Healthcare Co. Ltd., Beijing, China.

6. Pharmacovigilance, Benefit-Risk Management Oncology, Bayer AG, Berlin, Germany.

7. Strategic Business Unit Oncology, Bayer Healthcare US, Whippany, New Jersey, USA.

8. Strategic Business Unit Oncology, Bayer AG, Berlin, Germany.

9. Research and Development, Bayer AS, Oslo, Norway.

10. Department of Haematology, University College London Hospital, London, United Kingdom.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2020.4653

Reference21 articles.

1. Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

2. Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

3. Long-term outcome and mortality trends in early-stage, Grade 1–2 follicular lymphoma treated with radiation therapy

4. Targeted Alpha Therapy, an Emerging Class of Cancer Agents

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concept validation of separations for thorium-based radionuclide generator systems for medical application;Frontiers in Nuclear Engineering;2024-08-08

2. Activity standard and calibrations for 227Th with ingrowing progeny;Applied Radiation and Isotopes;2024-07

3. Nano-radiopharmaceuticals as therapeutic agents;Frontiers in Medicine;2024-03-15

4. Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma;Exploration of Targeted Anti-tumor Therapy;2024-02-28

5. Alpha-Emitting Radionuclides: Current Status and Future Perspectives;Pharmaceuticals;2024-01-08